Soluble CD163 and Soluble Mannose Receptor Predict Survival and Decompensation in Patients with Liver Cirrhosis, and Correlate with Gut Permeability and Bacterial Translocation

Overview

Journal Aliment Pharmacol Ther

Specialties Gastroenterology
Pharmacology

Date 2017 Dec 22

PMID 29266346

Citations 38

Authors

F Rainer

A Horvath

T D Sandahl

B Leber

B Schmerboeck

A Blesl

A Groselj-Strele

R E Stauber

P Fickert

P Stiegler

H J Moller

H Gronbaek

V Stadlbauer

Affiliations

Soon will be listed here.

Abstract

Background: Activated hepatic macrophages play a key role in inflammation and fibrosis progression in chronic liver disease.

Aim: To assess the prognostic value of soluble (s)CD163 and mannose receptor (sMR) in cirrhotic patients and explore associations with markers of intestinal permeability (lactulose-mannitol ratio, diamine oxidase), bacterial translocation (endotoxin, lipopolysaccharide-binding protein) and markers of systemic immune activation (interleukin-6, interleukin-8, sCD14).

Methods: We prospectively investigated 101 cirrhotic patients (Child-Pugh class A: n = 72, Child-Pugh classes B and C: n = 29) and 31 healthy controls. Patients were observed for a median follow-up of 37 months.

Results: Median plasma levels of sCD163 and soluble mannose receptor were significantly elevated in cirrhotic patients (P < .001) and increased with disease severity (sCD163 in healthy controls = 1.3, Child-Pugh class A = 4.2, Child-Pugh classes B and C = 8.4 mg/L; sMR in healthy controls = 15.8, Child-Pugh class A = 36.5, Child-Pugh classes B and C = 66.3 μg/dL). A total of 21 patients died during the observation period. Patients with sCD163 levels above 5.9 mg/L showed significantly reduced survival (survival rate after 36 months: 71% versus 98%, P < .001). Patients with soluble mannose receptor levels above 45.5 μg/dL developed significantly more complications of cirrhosis within 12 months (73% versus 9%, P < .001). Furthermore, both variables correlated with the lactulose-mannitol ratio, diamine oxidase, lipopolysaccharide and interleukin-8.

Conclusion: Our data demonstrate the prognostic value of sCD163 in predicting long-term survival in patients with liver cirrhosis and identify soluble mannose receptor as a prognostic marker for occurrence of cirrhosis-associated complications. The correlation between gut barrier dysfunction and activation of macrophages points towards a link between them.

Citing Articles

Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis.

Tiede A, Stockhoff L, Liu Z, Rieland H, Mauz J, Ohlendorf V Clin Mol Hepatol. 2024; 31(1):240-255.

PMID: 39568127 PMC: 11791575. DOI: 10.3350/cmh.2024.0587.

Oral administration of tea-derived exosome-like nanoparticles protects epithelial and immune barrier of intestine from psychological stress.

Gong Q, Sun Y, Liu L, Pu C, Guo Y Heliyon. 2024; 10(17):e36812.

PMID: 39281430 PMC: 11395767. DOI: 10.1016/j.heliyon.2024.e36812.

Physiological network approach to prognosis in cirrhosis: A shifting paradigm.

Oyelade T, Moore K, Mani A Physiol Rep. 2024; 12(13):e16133.

PMID: 38961593 PMC: 11222171. DOI: 10.14814/phy2.16133.

Different effects of acute and chronic oxidative stress on the intestinal flora and gut-liver axis in weaned piglets.

Zhang H, Xiang X, Wang C, Li T, Xiao X, He L Front Microbiol. 2024; 15:1414486.

PMID: 38952442 PMC: 11215049. DOI: 10.3389/fmicb.2024.1414486.

Macrophage Perspectives in Liver Diseases: Programmed Death, Related Biomarkers, and Targeted Therapy.

Qian Z, Xiong W, Mao X, Li J Biomolecules. 2024; 14(6).

PMID: 38927103 PMC: 11202214. DOI: 10.3390/biom14060700.

References

Schnabl B, Brenner D . Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014; 146(6):1513-24. PMC: 3996054. DOI: 10.1053/j.gastro.2014.01.020. View

Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T . Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus. J Viral Hepat. 2014; 22(4):427-32. DOI: 10.1111/jvh.12309. View

Fernando M, Reyes J, Iannuzzi J, Leung G, McKay D . The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLoS One. 2014; 9(4):e94188. PMC: 3988054. DOI: 10.1371/journal.pone.0094188. View

Horvath A, Leber B, Schmerboeck B, Tawdrous M, Zettel G, Hartl A . Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis. Aliment Pharmacol Ther. 2016; 44(9):926-935. PMC: 5053220. DOI: 10.1111/apt.13788. View

Rode A, Nicoll A, Moller H, Lim L, Angus P, Kronborg I . Hepatic macrophage activation predicts clinical decompensation in chronic liver disease. Gut. 2013; 62(8):1231-2. DOI: 10.1136/gutjnl-2012-304135. View

Kazankov K, Barrera F, Moller H, Bibby B, Vilstrup H, George J . Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology. 2014; 60(2):521-30. DOI: 10.1002/hep.27129. View

Hume D, Underhill D, Sweet M, Ozinsky A, Liew F, Aderem A . Macrophages exposed continuously to lipopolysaccharide and other agonists that act via toll-like receptors exhibit a sustained and additive activation state. BMC Immunol. 2001; 2:11. PMC: 58839. DOI: 10.1186/1471-2172-2-11. View

Baffy G . Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009; 51(1):212-23. PMC: 2694233. DOI: 10.1016/j.jhep.2009.03.008. View

Mokdad A, Lopez A, Shahraz S, Lozano R, Mokdad A, Stanaway J . Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014; 12:145. PMC: 4169640. DOI: 10.1186/s12916-014-0145-y. View

10.

Cavaillon J . Cytokines and macrophages. Biomed Pharmacother. 1994; 48(10):445-53. DOI: 10.1016/0753-3322(94)90005-1. View

11.

Funding M, Vorum H, Nexo E, Moestrup S, Ehlers N, Moller H . Soluble CD163 and interleukin-6 are increased in aqueous humour from patients with endothelial rejection of corneal grafts. Acta Ophthalmol Scand. 2005; 83(2):234-9. DOI: 10.1111/j.1600-0420.2005.00397.x. View

12.

Frey E, Miller D, Jahr T, Sundan A, Bazil V, Espevik T . Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med. 1992; 176(6):1665-71. PMC: 2119444. DOI: 10.1084/jem.176.6.1665. View

13.

Holland-Fischer P, Gronbaek H, Sandahl T, Moestrup S, Riggio O, Ridola L . Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut. 2011; 60(10):1389-93. DOI: 10.1136/gut.2010.234542. View

14.

Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C . A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33(2):464-70. DOI: 10.1053/jhep.2001.22172. View

15.

Gronbaek H, Rodgaard-Hansen S, Aagaard N, Arroyo V, Moestrup S, Garcia E . Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). J Hepatol. 2015; 64(4):813-22. DOI: 10.1016/j.jhep.2015.11.021. View

16.

Hanley J, McNeil B . A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983; 148(3):839-43. DOI: 10.1148/radiology.148.3.6878708. View

17.

Boltjes A, Movita D, Boonstra A, Woltman A . The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol. 2014; 61(3):660-71. DOI: 10.1016/j.jhep.2014.04.026. View

18.

Ritter M, Buechler C, Langmann T, Orso E, Klucken J, Schmitz G . The scavenger receptor CD163: regulation, promoter structure and genomic organization. Pathobiology. 2000; 67(5-6):257-61. DOI: 10.1159/000028105. View

19.

Uesugi T, Froh M, Arteel G, Bradford B, Thurman R . Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology. 2001; 34(1):101-8. DOI: 10.1053/jhep.2001.25350. View

20.

Wiest R, Lawson M, Geuking M . Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2013; 60(1):197-209. DOI: 10.1016/j.jhep.2013.07.044. View